DELCATH SYSTEMS, INC. (DCTH) Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Delcath Systems, Inc. NASDAQ:DCTH Healthcare · Medical - Devices
Mkt Cap $487.17M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Delcath Systems to Participate in Upcoming Investor Conferences
Delcath Systems announced management will attend three investor conferences in November 2026: the UBS Global Healthcare Conference, Canaccord Genuity's MedTech forum, and the Craig-Hallum Alpha Select Conference.
A live and archived webcast of the UBS conference presentation will be available on the company's investor website.
The release contains no new financial, clinical, or regulatory information; it is a routine investor-outreach notice.
• 5d ago AI analysis › Press Release
Delcath Systems to Host Third Quarter 2026 Earnings Call
Delcath Systems will host its third quarter 2026 earnings call on November 9, 2026, at 8:30 AM Eastern Time, covering results for the quarter ended September 30, 2026.
The release is a scheduling notice only, providing dial-in numbers and webcast details; no financial results are included.
Delcath is an interventional oncology company whose lead products are HEPZATO KIT (approved in the US for metastatic uveal melanoma) and CHEMOSAT in Europe.
• 6d ago AI analysis › Press Release ⚠ 2
Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
Delcath announced multiple presentations at ESMO Congress 2026 (Oct 23-27, Madrid), including a trial-in-progress poster for the DELUMA Phase 2 study of melphalan/HDS in liver-dominant metastatic breast cancer and a Del-Liver Phase 2 update in metastatic colorectal cancer.
An independent investigator-led retrospective (N=12) of CHEMOSAT percutaneous hepatic perfusion in liver-dominant metastatic uveal melanoma reported an ORR of 66.7%, disease control of 75%, median hepatic PFS of 18.4 months, and median overall survival of 28 months, with no treatment-related deaths.
The independent data support real-world use of Delcath's PHP platform outside its sponsored trials, though the small single-site cohort limits the strength of the evidence.
• 13d ago AI analysis › Press Release
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems granted inducement RSUs covering 34,000 shares of common stock to four individuals whose employment began in July or August 2026, under its 2023 Inducement Plan.
The awards were granted September 1, 2026 in accordance with Nasdaq Listing Rule 5635(c)(4), vesting one-third on the first anniversary with the remaining two-thirds vesting in equal annual installments over the following two years, contingent on continued employment.
This is routine new-hire equity compensation with negligible share count impact and no financial or operational signal for investors.
• 1mo ago AI analysis › Press Release
Delcath Systems to Participate in Upcoming Investor Conferences
Delcath Systems announced that management will attend the Wells Fargo Healthcare Conference in Boston on September 10, 2026, and the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 15, 2026.
The company is an interventional oncology firm focused on liver cancer, utilizing its proprietary HEPZATO KIT and CHEMOSAT systems to deliver high-dose chemotherapy while controlling systemic exposure.
HEPZATO KIT is FDA-approved in the U.S. for metastatic uveal melanoma, while the CHEMOSAT system is approved in Europe as a Class III medical device for treating liver cancers.
• 2mo ago AI analysis › Press Release ● Major ⚠ 1
Delcath Systems Reports Second Quarter 2026 Results and Business Highlights
Delcath Systems reported Q2 2026 revenue of $29.1 million, up from $24.2 million in the prior year, driven by a 30% increase in HEPZATO volume and expanding gross margins to 90%. The company generated $5.7 million in cash from operations and maintained a net income of $2.7 million.
Management raised full-year 2026 revenue guidance to a range of $104 million to $108 million, reflecting confidence in the adoption of HEPZATO across 31 active treatment centers.
The balance sheet remains robust with $95.9 million in cash and no debt, supporting ongoing R&D efforts including a new Phase 2 trial in metastatic breast cancer.
• 2mo ago AI analysis › Press Release
Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference
Delcath Systems management will attend the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, in Boston, MA.
The company specializes in interventional oncology for liver cancers, utilizing its proprietary Hepatic Delivery System (HDS) to administer high-dose chemotherapy with controlled systemic exposure.
Its primary products include HEPZATO KIT, an FDA-approved drug-device combo in the U.S. for metastatic uveal melanoma, and CHEMOSAT, a Class III medical device approved in Europe.
• 3mo ago AI analysis › Press Release
Delcath Systems to Host Second Quarter 2026 Earnings Call
Delcath Systems announced it will host a conference call on August 6, 2026 at 8:30 AM ET to discuss financial results for the second quarter ended June 30, 2026.
Investors can participate via toll-free or international dial-in numbers, with a live webcast and replay available on the company's website.
The company is an interventional oncology firm focused on liver cancers, utilizing proprietary products HEPZATO KIT and CHEMOSAT to administer high-dose chemotherapy with controlled systemic exposure.
• 3mo ago AI analysis › Press Release
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems granted 17,000 RSUs to four new employees as employment inducements approved by its Compensation Committee.
The RSUs vest annually over three years beginning July 1, 2027, subject to continued employment.
The company focuses on interventional oncology for liver cancer, utilizing its HEPZATO KIT and CHEMOSAT systems.
• 3mo ago AI analysis › Press Release
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
Delcath Systems has dosed the first patient in its global Phase 2 DELUMA trial evaluating HEPZATO for liver-dominant metastatic breast cancer.
The trial, initiated at the European Institute of Oncology in Milan, will enroll approximately 90 patients across more than 20 sites in the US and Europe.
Management estimates 7,000 US patients annually are candidates for this third-line treatment, highlighting the potential market expansion beyond the company's approved uveal melanoma indication.
• 3mo ago AI analysis › Press Release
Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
Delcath Systems announced two investigator-initiated trials-in-progress abstracts to be presented at the 2026 ASCO Annual Meeting in Chicago.
The first abstract (TPS9605) describes a Phase 2 trial evaluating sequential treatment with HEPZATO followed by tebentafusp in metastatic uveal melanoma with liver metastases. The study opened for enrollment in November 2025.
The second abstract (TPS9600) outlines a Phase 1b/2 study combining HEPZATO with nivolumab and relatlimab as a first-line treatment for metastatic non-uveal melanoma with liver involvement. This study opened for enrollment in January 2026.
• 5mo ago AI analysis › Press Release
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems granted 24,500 Restricted Stock Units to four new employees who commenced employment in March or April 2026.
The awards were issued as material inducements under Nasdaq Listing Rule 5635(c)(4) and the company’s 2023 Inducement Plan.
The RSUs vest over three years, with one-third vesting on the first anniversary and the remainder in equal annual installments.
• 5mo ago AI analysis › Press Release
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
businesswire.com • 5mo ago Press Release ● Major
Delcath Systems Reports First Quarter 2026 Results and Business Highlights
businesswire.com • 5mo ago Press Release ⚠ 2
Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026
Delcath Systems presented retrospective data at ESMO Breast Cancer 2026 showing a 60% hepatic partial response rate for its CHEMOSAT system in liver-dominant metastatic breast cancer.
The analysis of 15 heavily pre-treated patients demonstrated a median overall survival of 6.0 months, validating the liver-directed approach.
These findings support the ongoing Phase 2 PHP-MBC-202 trial evaluating HEPZATO KIT in this indication.
• 5mo ago AI analysis › Press Release
Delcath Systems to Host First Quarter 2026 Earnings Call
Delcath Systems announced it will host a conference call on May 7, 2026, at 8:30 AM ET to discuss its first quarter financial results for the period ended March 31, 2026.
Investors can participate via telephone using domestic or international dial-in numbers or access the live audio webcast through the company's website.
A replay of the presentation will be archived and available online shortly after the call concludes.
• 6mo ago AI analysis › 
